Replidyne Shelves Faropenem Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Potential partners may have been scared off by challenging trial designs, analyst tells “The Pink Sheet” DAILY.
You may also be interested in...
Stuck In Reverse: Another Start-up Takes Reverse Merger Route To Public Markets
Deal results in unlikely combination of antbiotics maker Replidyne and device firm Cardiovascular Systems.
Stuck In Reverse: Another Start-up Takes Reverse Merger Route To Public Markets
Deal results in unlikely combination of antbiotics maker Replidyne and device firm Cardiovascular Systems.
FDA Slaps Replidyne With Faropenem Warning
Dubious trials were done several years ago by Bayer, Replidyne tells “The Pink Sheet” DAILY.